Actovegin vs PEA (Palmitoylethanolamide)

Overview

Actovegin and PEA (Palmitoylethanolamide) are both pain management peptides, but they differ in mechanism, dosing, and regulatory status.

This page compares Actovegin and PEA (Palmitoylethanolamide) across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.

Side-by-side comparison

Key differences

Primary use. Actovegin is categorised under Pain Management, while PEA (Palmitoylethanolamide) falls under Pain Management. Because they target a similar goal, they are common alternatives to weigh against each other.

Regulatory status. Actovegin: not FDA-approved; treated as a research compound. PEA (Palmitoylethanolamide): not FDA-approved; treated as a research compound.

Dosing. Actovegin is typically dosed at 5-10 ml (multiple weekly). PEA (Palmitoylethanolamide) is typically dosed at 300-600 mg (twice daily).

Can you stack them?

Some protocols combine peptides, but stacking Actovegin and PEA (Palmitoylethanolamide) has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.

Frequently asked questions

What is the difference between Actovegin and PEA (Palmitoylethanolamide)?

Actovegin and PEA (Palmitoylethanolamide) are both pain management peptides, but they differ in mechanism, dosing, and regulatory status. Actovegin is not FDA-approved; generally classified as a research compound, whereas PEA (Palmitoylethanolamide) is not FDA-approved; generally classified as a research compound.

What is Actovegin used for?

Hypoxic pain and healing.

What is PEA (Palmitoylethanolamide) used for?

Natural pain modulator.

Can you take Actovegin and PEA (Palmitoylethanolamide) together?

Some users combine peptides within a single protocol, but stacking Actovegin and PEA (Palmitoylethanolamide) has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.

Is Actovegin or PEA (Palmitoylethanolamide) FDA-approved?

Actovegin is not FDA-approved; generally classified as a research compound. PEA (Palmitoylethanolamide) is not FDA-approved; generally classified as a research compound.